Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · May 03, 2012

Bevacizumab Effective in Platinum-Sensitive Recurrent Ovarian Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
J. Clin. Oncol 2012 Apr 23;[EPub Ahead of Print], C Aghajanian, SV Blank, BA Goff, PL Judson, MG Teneriello, A Husain, MA Sovak, J Yi, LR Nycum

Further Reading